What is the association between the tumor necrosis factor-alpha inhibitor infliximab and complex regional pain syndrome type I?
Paraskevas
Kosmas I
KI
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D016207:Cytokines / Q000187:drug effects; D006801:Humans; D000069285:Infliximab; D012019:Reflex Sympathetic Dystrophy / Q000139:chemically induced / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab